While I share your opinion about board members and gravy train's this is an interesting development.
Insulet ($PODD) has a contract with Amgen to supply a wearable device for Nuelasta. Additionally Orbimed was invested in PODD up until August of last year prior to the commencement of the strategic review which ended up with Amgen becoming a strategic partner. This appointment adds depth with someone who has practical knowledge of the wearable space both for biologic delivery and insulin delivery.
Aditionally $PODD is owned almost entirely by the big institutional guys so this guy is well know on the street.
https://www.medtechintelligence.com...-insulet-explores-viable-smart-drug-delivery/
Additionally don't forget Insulet also makes a wearable insulin pump for type I diabetes.
IMO he was a good get.
- Forums
- ASX - By Stock
- UNS
- New Directors to the Board
New Directors to the Board, page-3
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online